NasdaqGS:SRPTBiotechs
A Look at Sarepta Therapeutics (SRPT) Valuation Following Mixed ESSENCE Trial Results and Earnings Shift
Sarepta Therapeutics (SRPT) shares drew attention after the company announced mixed outcomes from its pivotal ESSENCE Phase 3 trial. Although the main goal did not reach statistical significance, trends leaned positive for their therapies.
See our latest analysis for Sarepta Therapeutics.
Sarepta’s ESSENCE trial update and a sharp swing from net income to net loss in the recent quarter have weighed on sentiment, reflected in its 1-year total shareholder return of -84%. While shares are off...